As Dr. JoAnn Manson puts it, the main problem with postmenopausal hormone therapy is that women are being treated for treatment, rather than overtreatment.
This is why the Harvard University school of medicine, women’s health department Manson (Manson) is one of several climacteric experts, he questioned the U.S. preventive services task force (USPSTF) whether need on Tuesday issued a different update proposal in 2002, 2005 and 2012 in postmenopausal hormone therapy stance: women should not take it as to reduce the risk of chronic diseases such as heart disease’s age. (as stated in its website, the USPSTF is an independent panel of volunteer prevention and evidence-based medicine.
University of Manchester (Manson) was the lead researcher of the landmark project, he said: “since 2002,” the women’s health initiative “report, since the use of hormone therapy to prevent cardiovascular disease is extremely rare. “I think these new guidelines may confuse women and their clinician.”
When the national institutes of health in 1991 launched the women’s health initiative (WHI), there are many postmenopausal women and their doctors think menopause is a lack of disease, need to accept hormone replacement therapy to alleviate the effects of aging. But the idea is based primarily on observational studies where women decide whether to continue hormone therapy. While other factors may be trustworthy for better health for hormone users, observational studies can’t answer that question.
But in one experiment, women were randomly assigned hormone therapy or placebo pills, one of the main reasons the NIH invested millions of dollars in WHI. A WHI study randomly assigned 16,600 postmenopausal women who did not receive the most commonly used estrogen plus progesterone treatment for Prempro or placebo hysterectomy. (women still in the womb must be treated with hormone therapy because estrogen alone increases the risk of endometrial cancer (endometrium). Another WHI study randomly assigned 11,000 healthy postmenopausal women, the most commonly used estrogen hormone treatment, or the placebo of Premarin hysterectomy.
The two clinical trials were halted in 2002 and 2004 respectively, because the researchers found that hormone therapy did more harm than good. In estrogen plus progestin trial, WHI found an increased risk of invasive breast cancer, and specify the treatment of women suffering from lung disease, coronary heart disease, strokes and blood clots, but fewer cases of hip fractures and colorectal cancer. In studies using estrogen alone, hormone therapy appears to have no effect on heart disease or breast cancer, but increases the risk of stroke, reducing the risk of hip fracture.
Following the results of a combined treatment trial published in July 2002, the annual hormone therapy prescription plummeted. Compared with the first half of 2002, although the WHI Premarin test is still ongoing, the number of prescriptions in the first half of 2003 has been reduced by two-thirds, Prempro is down by two-thirds and Premarin by a third. Manson told me that today, postmenopausal hormone therapy is 80 percent lower than in its heyday before WHI.
Unfortunately, she said that women and their doctors almost gave up on hormone therapy, as treatment of hot flashes and night sweats – could interrupt three-quarters of the women in the menopausal transition reported symptoms. At the same time, its members on menopausal women’s professional organization (including the American college of obstetricians and gynaecologists, north American menopause society and endocrine society) that hormone therapy is still the most effective treatment, Manson and co-author Andrew Kaunitz Dr In the “New England journal of medicine,” a perspective article in 2016, severe hot flashes and night sweats.